Benitec Biopharma Inc. BNTC
9.28 USD -0.59 (-5.98%)
At closeNov 10, 2026, 4:00 PM EST
9.28 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
9.24 Day range 10.01
8.11 52-week range 14.08
- YTD
- -31.11%
- 1 year
- -28.01%
News
benzinga.com Benitec Biopharma Announces Its Interim Data From BB-301 Phase 1b/2a Trial Shows Continued Durable Enhancements In Participants Treated With Low Dose Of BB-301; 100% Response Rate Seen Across All Patients Treated Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and
globenewswire.com Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 - Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with…
benzinga.com This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.
benzinga.com Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14 Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.
defenseworld.net Benitec Biopharma (NASDAQ:BNTC) Share Price Breaks Below 50-Day Moving Average – Here’s What Happened Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) shares passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $11.14 and traded as…
globenewswire.com Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study The BB-301 pivotal trial remains on track to begin in mid-2027 Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested…
defenseworld.net Benitec Biopharma (NASDAQ:BNTC) Stock Crosses Below 50 Day Moving Average – Here’s Why Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report)'s share price crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $12.08 and traded…
zacks.com After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC) Benitec Biopharma (BNTC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings…
defenseworld.net Benitec Biopharma (BNTC) Projected to Release Quarterly Earnings on Monday Benitec Biopharma (NASDAQ: BNTC - Get Free Report) is expected to announce its Q4 2026 results before the market opens on Monday, September 28th. Analysts expect Benitec Biopharma to announce…
benzinga.com Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17 Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.
benzinga.com Benitec Biopharma Q4 EPS $(0.26), Inline Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 38.1 percent increase over losses of $(0.42) per share from the same…
globenewswire.com Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been…
defenseworld.net AWM Investment Company Inc. Acquires New Position in Benitec Biopharma Limited $BNTC AWM Investment Company Inc. acquired a new position in Benitec Biopharma Limited (NASDAQ: BNTC) in the second quarter, according to its most recent 13F filing with the Securities and Exchange…
benzinga.com This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.
benzinga.com Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16 Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $16.
globenewswire.com Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and…
globenewswire.com Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting - Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the…
globenewswire.com Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel…
globenewswire.com Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference -Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first…
seekingalpha.com Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
globenewswire.com Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response • Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with…
defenseworld.net Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Buys 16,836 Shares Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L bought 16,836 shares of the firm's stock in a transaction that occurred on Friday, December 26th.…
defenseworld.net Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Acquires 50,000 Shares Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L purchased 50,000 shares of Benitec Biopharma stock in a transaction that occurred on Tuesday,…
zacks.com Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect? The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable,…
defenseworld.net Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Purchases 10,215 Shares of Stock Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L bought 10,215 shares of the business's stock in a transaction on Thursday, December 18th. The stock…
zacks.com Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
zacks.com Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) Benitec Biopharma (BNTC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Market-Moving News for April 18th BPTH: 98% | Bio-Path Holdings shares are trading higher after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to…
benzinga.com Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket Gainers Axcella Health Inc. (NASDAQ: AXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss.- benzinga.com Why Cutera Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Wednesday's Session Gainers Tango Therapeutics, Inc. (NASDAQ: TNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesday. Tango Therapeutics recently posted a narrower quarterly loss.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 155 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 188 companies set new 52-week lows.
- benzinga.com Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market.
- benzinga.com Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 413 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 101 companies made new 52-week lows.
benzinga.com 121 Stocks That Hit Their 52-Week Low New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 429 stocks made new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 574 stocks hit new 52-week lows.
- benzinga.com Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX…
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 126 companies set new 52-week lows.
benzinga.com Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in…- benzinga.com Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to…
- benzinga.com Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 297 companies achieved new lows for the year.
- benzinga.com Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per…
- benzinga.com Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.